Single-cell RNA and bulk sequencing analysis reveals that formononetin inhibits GTSF1 to exert anti-osteosarcoma effects.

version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes pmc-license-ref CC BY-NC crossmark INTRODUCTION As the most common primary malignant bone tumor, osteosarcoma (OS) predominantly occurs in children and adolescents, with an incidence rate of 3–4 per million, showing an increasing trend. 1–3 Currently, the standard therapeutic schedule for OS includes surgical resection and adjuvant chemotherapy, with agents such as cisplatin, doxorubicin, ifosfamide, and high-dose methotrexate. 4,5 However, the toxic side effects and resistance to chemotherapy limit patient benefits.

also in 63,971 other papers